Latest & greatest articles for quetiapine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on quetiapine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on quetiapine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for quetiapine

1. Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials

Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials Cheung G, Stapelberg J CRD summary The authors concluded (...) that, using the Neuropsychiatric Inventory and the Clinical Global Impression of Change scale,quetiapine was statistically more effective than placebo for the behavioural and psychological symptoms of dementia in elderly people; the clinical significance of the effects was questionable. Limitations to the review methods mean that the reliability of the authors' conclusion is unclear. Authors' objectives To evaluate the efficacy of quetiapine for the behavioural and psychological symptoms of dementia

2011 DARE.

2. Evaluation of Trazodone and Quetiapine for Insomnia: An Observational Study in Psychiatric Inpatients Full Text available with Trip Pro

Evaluation of Trazodone and Quetiapine for Insomnia: An Observational Study in Psychiatric Inpatients Insomnia is symptomatic of most psychiatric disorders. Non-habit-forming agents such as trazodone and quetiapine are commonly used off-label to treat patients with insomnia. The safety and efficacy of trazodone and quetiapine as medications for treatment of insomnia have never been directly contrasted. The objective of this study was to compare the effectiveness of trazodone to quetiapine among (...) inpatient psychiatric patients by measuring the traditional sleep parameters of total sleep time, number of nighttime awakenings, sleep efficiency, sleep latency, length of hospitalization, and patient-reported side effects.Participants were recruited from St Helena Hospital Center for Behavioral Health, Vallejo, California. Patient inclusion criteria were age 18 to 65 years, admitted between September 2011 and February 2012, and a physician order for trazodone or quetiapine for insomnia. Exclusion

2013 The Primary Care Companion for CNS Disorders

3. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis

Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

4. Quetiapine

Quetiapine Top results for quetiapine - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for quetiapine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

5. Is use of quetiapine for sleep evidence-based?

Is use of quetiapine for sleep evidence-based? September - December 2010 79 © Tel.: 604 822•0700 Fax: 604 822•0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Is use of quetiapine for sleep evidence-based? The healthy subject study evaluated 14 males using a randomized, double-blind, crossover, placebo-controlled (...) , single-center design. Placebo or quetiapine at 25 and 100 mg doses were given on 3 consecutive nights with a 4-day washout period before crossover. Polysomnographic recordings were made nightly and subjective sleep-rating questionnaires completed each morn- ing. Both doses of quetiapine produced statisti- cally significant improvements in objective and subjective ratings of sleep, including total sleep time, sleep efficiency, sleep latency and duration of stage 2 sleep. The 100 mg dose increased peri

2011 Therapeutics Letter

6. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Full Text available with Trip Pro

Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. This study evaluated once-daily extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in patients with major depressive disorder (MDD) with inadequate response to ongoing antidepressant treatment. In this 8-wk (6-wk active (...) treatment/2-wk post-treatment drug-discontinuation/follow-up), multicentre, double-blind, placebo-controlled, Phase III study, 446 patients were randomized to quetiapine XR 150 mg/d, 300 mg/d, or placebo adjunct to ongoing antidepressant treatment. The primary endpoint was the change from randomization to week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) total score. At week 6, MADRS total scores significantly improved with quetiapine XR 300 mg/d vs. placebo (-14.7 vs. -11.7, p<0.01

2010 The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) Controlled trial quality: uncertain

7. Generalised anxiety disorder: quetiapine

Generalised anxiety disorder: quetiapine Gener Generalised anxiety disorder: quetiapine alised anxiety disorder: quetiapine Evidence summary Published: 15 May 2013 nice.org.uk/guidance/esuom12 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in May 2013. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information. Summary There is some evidence (...) that quetiapine monotherapy improves the symptoms of generalised anxiety disorder (GAD) compared with placebo, and limited evidence suggests that it is not more effective than antidepressants. Other limited evidence suggests that adding quetiapine to an antidepressant does not improve symptoms in GAD that has not responded to the antidepressant alone. People taking quetiapine are more likely to discontinue treatment because of adverse effects compared with placebo or active treatment. Licencing status

2013 National Institute for Health and Clinical Excellence - Advice

8. Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium

Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium (Haloquet) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01811459 Recruitment Status : Completed First Posted : March 14, 2013 Last Update Posted : February 9, 2018

2013 Clinical Trials

9. Comparison of the efficacy and safety of quetiapine XR and quetiapine IR for bipolar depression: a meta-analysis of double-blind, randomized placebo-controlled trials

Comparison of the efficacy and safety of quetiapine XR and quetiapine IR for bipolar depression: a meta-analysis of double-blind, randomized placebo-controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

10. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials Efficacy and extrapyramidal side-effects of the new (...) antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials Leucht S, Pitschel-Walz G, Abraham D, Kissling W Authors' objectives To summarise the efficacy and tolerability of the new antipsychotics risperidone, olanzapine, sertindole and quetiapine in schizophrenia compared to placebo and conventional antipsychotics. Searching MEDLINE (1966-January 1998) and Current Contents (1966-March 1998) were

1999 DARE.

11. Aripiprazole versus quetiapine in treatment-resistant obsessive–compulsive disorder: a double-blind clinical trial Full Text available with Trip Pro

Aripiprazole versus quetiapine in treatment-resistant obsessive–compulsive disorder: a double-blind clinical trial Around 40-60% of the patients with obsessive-compulsive disorder (OCD) remain unimproved by serotonin reuptake inhibitors (SRIs). Goal of this study was to compare the efficiency and safety of aripiprazole versus quetiapine, in patients with OCD, who did not respond effectively to fluvoxamine.A total of 44 female inpatients with OCD, who did not respond successfully (...) to fluvoxamine at maximum dose (300 mg/day) and duration (12 weeks), were assigned randomly, in a double-blind trial, to receive aripiprazole (n = 22) or quetiapine (n = 22), in addition to their SRI, for 12 weeks. Treatment response was assessed by the Yale-Brown Obsessive-Compulsive Scale (YBOCS), as primary outcome measure, and Clinical Global Impressions-Severity Scale (CGI-S), as a secondary outcome measure.A total of 27.27% of the cases in the aripiprazole group (n = 6) and 54.54% of them

2015 Therapeutic Advances in Psychopharmacology Controlled trial quality: uncertain

12. Quetiapine as combination treatment with citalopram in unipolar depression with prominent somatic symptoms: a randomised, double-blind, placebo-controlled pilot study. (Abstract)

Quetiapine as combination treatment with citalopram in unipolar depression with prominent somatic symptoms: a randomised, double-blind, placebo-controlled pilot study. Patients with major depressive disorder (MDD) accompanied by physical symptoms may be less responsive to antidepressant treatment. Quetiapine has been evaluated in the treatment of bipolar depression and has been recently approved as an add-on therapy for unipolar depression. Less is known about the efficacy of combination (...) therapies in patients suffering from MDD with somatic symptoms. The aim of the present study was to evaluate the efficacy of quetiapine as adjunctive therapy to the SSRI citalopram in patients with MDD and somatic complaints.41 inpatients with nonpsychotic DSM-IV MDD experiencing significant symptoms of somatic distress as defined by a baseline score on the SCL-90-R somatization subscale greater one standard deviation above adult nonpatient norms were randomly assigned to receive either citalopram 40 mg

2013 Psychiatria Danubina

13. The Effects of Quetiapine on Sleep in Recovering Alcohol-Dependent Subjects: A Pilot Study. (Abstract)

The Effects of Quetiapine on Sleep in Recovering Alcohol-Dependent Subjects: A Pilot Study. The aim of this hypothesis-generating pilot study was to assess prospectively the objective and subjective effects of treatment with quetiapine XR on sleep during early recovery from alcohol dependence (AD).Recovering subjects with AD and sleep disturbance complaints were treated with quetiapine XR (n = 10) or matching placebo pills (n = 10) for 8 weeks. Polysomnography was used to assess sleep (...) of quetiapine XR on sleep efficiency (time spent asleep/total recording time), there was a pre-to-post reduction in wake after sleep onset time (P = 0.03) and nonsignificant trends for increases in sleep onset latency (SOL) and stage 2 sleep time. A time × drug interaction was seen for the subjective insomnia, such that quetiapine XR-treated subjects reported greater initial improvement in their subjective insomnia, but the difference was not sustained. There were no differences between treatment groups

2014 Journal of Clinical Psychopharmacology Controlled trial quality: uncertain

14. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. (Abstract)

Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. This 6-week, randomized, double-blind study evaluated efficacy and safety of adjunctive extended-release (XR) quetiapine in patients with major depressive disorder (MDD) and an inadequate response to >or= 1 antidepressant.Male or female patients aged 18 to 65 years with DSM-IV-TR MDD were randomly assigned to receive quetiapine (...) the study. The study was conducted between May 8, 2006, and April 7, 2007.Four hundred ninety-three patients were randomly assigned. Mean change from randomization to week 6 in MADRS score was -15.26 and -14.94 for quetiapine XR 150 mg/day and 300 mg/day, respectively (both p < .01 vs. placebo [-12.21]). Quetiapine XR showed separation from placebo in MADRS score from week 1 (p < .001) onward. The MADRS response rates were 55.4%, 57.8%, and 46.3% for quetiapine XR 150 mg/day (p = .107 vs. placebo), 300

2009 Journal of Clinical Psychiatry Controlled trial quality: predicted high

15. Low doses of mirtazapine or quetiapine for transient insomnia: A randomised, double-blind, cross-over, placebo-controlled trial. (Abstract)

Low doses of mirtazapine or quetiapine for transient insomnia: A randomised, double-blind, cross-over, placebo-controlled trial. Low doses of the antidepressant mirtazapine or the neuroleptic quetiapine are often prescribed off-label for insomnia. However, studies on the effects on sleep and hangover effects the following day are scarce. In this randomised, double-blind, cross-over, placebo-controlled trial, the influence of 7.5 mg mirtazapine and 50 mg quetiapine on both normal sleep and sleep (...) disturbed by acoustic stress (traffic noise) as a model for transient insomnia was assessed. Additionally, hangover effects on next-day alertness and cognitive functioning were examined. A total of 19 healthy men without sleep complaints completed three treatment sessions, each session consisting of three consecutive nights in one of the mirtazapine, quetiapine or placebo conditions. Sleep was assessed using polysomnography and the Leeds Sleep Evaluation Questionnaire. Daytime sleepiness and cognitive

2017 Journal of psychopharmacology (Oxford, England) Controlled trial quality: uncertain

16. Comparative effectiveness of quetiapine and haloperidol in delirium: A single blind randomized controlled study. Full Text available with Trip Pro

Comparative effectiveness of quetiapine and haloperidol in delirium: A single blind randomized controlled study. To evaluate the effectiveness of quetiapine and haloperidol in patients of delirium referred to psychiatry consultation liaison services.The study followed a single blind randomised controlled trial design. Thirty-two patients in the haloperidol group and 31 patients in the quetiapine group were assessed at the baseline and 6 consecutive days. Flexible dosing regimen (haloperidol (...) : 0.25-1.25 mg; quetiapine 12.5-75 mg/d) was used. Delirium Rating Scale-Revised-98 (DRS-R-98) and mini mental status examination (MMSE) were the primary and secondary efficacy measures respectively.Baseline DRS-R-98 severity score and MMSE scores did not differ between the 2 study groups. From baseline to day 6, there was significant reduction in the total DRS-R-98 scores, DRS-R-98 cognitive domain scores, DRS-R-98 non-cognitive domain scores and significant increase in the MMSE scores in both

2016 World journal of psychiatry Controlled trial quality: uncertain

17. Quetiapine

Quetiapine Quetiapine - Wikipedia Quetiapine From Wikipedia, the free encyclopedia Quetiapine Clinical data Pronunciation Seroquel, Temprolide, others / : (Risk not ruled out) ( ) Legal status (Prescription only) (Prescription only) data 100% 83% via CYP3A4-catalysed sulfoxidation to its active metabolite norquetiapine (N-desalkylquetiapine) 7 hours (parent compound); 9–12 hours (active metabolite, norquetiapine) (73%), faeces (20%) Identifiers 2-(2-(4-Dibenzo[ b , f ][1,4]thiazepine-11-yl-1 (...) -piperazinyl)ethoxy)ethanol Y Y Y Y Y Y Chemical and physical data C 21 H 25 N 3 O 2 S 383.5099 g/mol g·mol −1 3D model ( ) 3.29 mg/mL (20 °C) N\1=C(\c3c(Sc2c/1cccc2)cccc3)N4CCN(CCOCCO)CC4 InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2 Y Key:URKOMYMAXPYINW-UHFFFAOYSA-N Y Quetiapine , sold under the trade name Seroquel among others, is an used for the treatment of , , and . Although not recommended, it is also used as a sleep aid due

2012 Wikipedia

18. Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression

Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression Article Text Therapeutics Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression

2010 Evidence-Based Mental Health

19. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol

Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol Kongsakon R, Leelahanaj T, Price N (...) , Birinyi-Strachan L, Davey P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Several medications for schizophrenia were examined. The four atypical antipsychotics studied were olanzapine (OLZ), risperidone (RISP), quetiapine (QUET

2005 NHS Economic Evaluation Database.

20. Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode

Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode Ekman M, Lindgren P, Miltenburger C, Meier G, Locklear JC, Chatterton ML Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of pharmacological treatments in all phases of bipolar disorder, comparing quetiapine with olanzapine and olanzapine plus lithium as well as with other

2013 NHS Economic Evaluation Database.